Progressive sarcoma Kaposi after COVID-19
Keywords:
Sarcoma Kaposi, COVID-19, immunosupression, HHV-8, SARS-CoV-2Abstract
This article deals with the sarcoma kaposi worsening after severe coronavirus infection.After 2 years of sarcoma Kaposi remission a 70-year-old male HIV-negative patient noted new violaceous skin nodules. A few months before he recovered from COVID-19. We present the case and review of literature.References
Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5(1):9. Published 2019 Jan 31. doi:10.1038/s41572-019-0060-9
https://ictv.global/taxonomy/taxondetails?taxnode_id=202101510
Katano H. Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection. Adv Exp Med Biol. 2018;1045:357-376. doi:10.1007/978-981-10-7230-7_16
Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021;113(2):70-84. doi:10.32074/1591-951X-213
Tembo R, Kaile T, Kafita D, et al. Detection of Human Herpes Virus 8 in Kaposi's sarcoma tissues at the University Teaching Hospital, Lusaka, Zambia. Pan Afr Med J. 2017;27:137. Published 2017 Jun 22. doi:10.11604/pamj.2017.27.137.11845
Pereira PF, Cuzzi T, Galhardo MC. Immunohistochemical detection of the latent nuclear antigen-1 of the human herpesvirus type 8 to differentiate cutaneous epidemic Kaposi sarcoma and its histological simulators. An Bras Dermatol. 2013;88(2):243-246. doi:10.1590/S0365-05962013000200010
Denis D et al. A fifth subtype of Kaposi’s sarcoma, classic Kaposi’s sarcoma in men who have sex with men: a cohort study in Paris. J. Eur. Acad. Dermatol. Venereol. 32, 1377–1384 2018
Mariggiò G, Koch S, Schulz TF. Kaposi sarcoma herpesvirus pathogenesis. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732):20160275. doi:10.1098/rstb.2016.0275
Calabresi A, Ferraresi A, Festa A, et al. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009. HIV Med. 2013;14(8):481-490. doi:10.1111/hiv.12034
Semeere AS, Busakhala N, Martin JN. Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings. Curr Opin Oncol. 2012;24(5):522-530. doi:10.1097/CCO.0b013e328355e14b
Liu Z, Fang Q, Zuo J, Minhas V, Wood C, Zhang T. The world-wide incidence of Kaposi's sarcoma in the HIV/AIDS era. HIV Med. 2018;19(5):355-364. doi:10.1111/hiv.12584
Robey RC, Bower M. Facing up to the ongoing challenge of Kaposi's sarcoma. Curr Opin Infect Dis. 2015;28(1):31-40. doi:10.1097/QCO.0000000000000122#
Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev. 2003;67(2):175-212. doi:10.1128/MMBR.67.2.175-212.2003
Grabar S, Costagliola D. Epidemiology of Kaposi's Sarcoma. Cancers (Basel). 2021;13(22):5692. Published 2021 Nov 14. doi:10.3390/cancers13225692
Cahoon EK, Linet MS, Clarke CA, Pawlish KS, Engels EA, Pfeiffer RM. Risk of Kaposi sarcoma after solid organ transplantation in the United States. Int J Cancer. 2018;143(11):2741-2748. doi:10.1002/ijc.31735
Esser S, Schöfer H, Hoffmann C, et al. S1 Guidelines for the Kaposi Sarcoma. J Dtsch Dermatol Ges. 2022;20(6):892-904. doi:10.1111/ddg.14788
Denis D, Seta V, Regnier-Rosencher E, et al. A fifth subtype of Kaposi's sarcoma, classic Kaposi's sarcoma in men who have sex with men: a cohort study in Paris. J Eur Acad Dermatol Venereol. 2018;32(8):1377-1384. doi:10.1111/jdv.14831
Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis. 2012;54(3):424-433. doi:10.1093/cid/cir802
Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005;352(13):1317-1323. doi:10.1056/NEJMoa042831
Nichols LA, Adang LA, Kedes DH. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PLoS One. 2011;6(1):e14535. Published 2011 Jan 14. doi:10.1371/journal.pone.0014535
FM Buonaguro; ML Tornesello; L Buonaguro; RA Satriano; E Ruocco; G Castello; V Ruocco (2003). Kaposi's sarcoma: aetiopathogenesis, histology and clinical features. , 17(2), 138–154. doi:10.1046/j.1468-3083.2003.00670.x
Koop, H. O., Holodniy, M., & List, A. F. (1987). Fulminant Kaposi’s sarcoma complicating long-term corticosteroid therapy. The American Journal of Medicine, 83(4), 787–789. doi:10.1016/0002-9343(87)90916-8
Hertzler G, Gordon SM, Piratzky J, Henderson JM, Gal AA. Case report: fulminant Kaposi's sarcoma after orthotopic liver transplantation. Am J Med Sci. 1995;309(5):278-281. doi:10.1097/00000441-199530950-00007
Etemad, Shervin A, and Anna K Dewan. “Kaposi Sarcoma Updates.” Dermatologic clinics vol. 37,4 (2019): 505-517. doi:10.1016/j.det.2019.05.008
Lebbe C, Garbe C, Stratigos AJ, et al. Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer. 2019;114:117-127. doi:10.1016/j.ejca.2018.12.036
Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci. 2021;58(5):297-310. doi:10.1080/10408363.2020.1860895
Melnikova VO, Dobroff AS, Zigler M, et al. CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One. 2010;5(8):e12452. Published 2010 Aug 27. doi:10.1371/journal.pone.0012452
Daniel P, Filiz G, Brown DV, et al. Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation. Oncogenesis. 2014;3(6):e108. Published 2014 Jun 30. doi:10.1038/oncsis.2014.21
Zhou M, Liu X, Li Z, Huang Q, Li F, Li CY. Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. Int J Cancer. 2018;143(4):921-930. doi:10.1002/ijc.31374
Ebrahimi Sadrabadi A, Bereimipour A, Jalili A, Gholipurmalekabadi M, Farhadihosseinabadi B, Seifalian AM. The risk of pancreatic adenocarcinoma following SARS-CoV family infection. Sci Rep. 2021;11(1):12948. Published 2021 Jun 21. doi:10.1038/s41598-021-92068-4
Alpalhão M, Ferreira JA, Filipe P. Persistent SARS-CoV-2 infection and the risk for cancer. Med Hypotheses. 2020;143:109882. doi:10.1016/j.mehy.2020.109882
Policard M, Jain S, Rego S, Dakshanamurthy S. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism. Virus Res. 2021;301:198464. doi:10.1016/j.virusres.2021.198464
Dursun R, Temiz SA. The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease. Dermatol Ther. 2020;33(4):e13730. doi:10.1111/dth.13730
Saade A, Moratelli G, Azoulay E, Darmon M. Herpesvirus reactivation during severe COVID-19 and high rate of immune defect. Infect Dis Now. 2021;51(8):676-679. doi:10.1016/j.idnow.2021.07.005
Nasrullah A, Patel S, Ud Din MT, et al. A case of acquired immunodeficiency syndrome-related Kaposi sarcoma in a patient with COVID-19 - A brief review of HIV-COVID Co-infection and its Therapeutic challenges!. Respir Med Case Rep. 2021;34:101524. doi:10.1016/j.rmcr.2021.101524
Gardini G, Odolini S, Moioli G, et al. Disseminated Kaposi sarcoma following COVID-19 in a 61-year-old Albanian immunocompetent man: a case report and review of the literature. Eur J Med Res. 2021;26(1):152. Published 2021 Dec 20. doi:10.1186/s40001-021-00620-9
Magri F, Giordano S, Latini A, Muscianese M. New-onset cutaneous kaposi's sarcoma following SARS-CoV-2 infection. J Cosmet Dermatol. 2021;20(12):3747-3750. doi:10.1111/jocd.1454
Aram K, Patil A, Goldust M, Rajabi F. COVID-19 and exacerbation of dermatological diseases: A review of the available literature. Dermatol Ther. 2021;34(6):e15113. doi:10.1111/dth.15113
Temiz SA, Kutlu Ö. The development of dermatologic diseases in patients recovered from COVID-19. Dermatol Ther. 2021;34(2):e14791. doi:10.1111/dth.14791
Leoni E, Cerati M, Finzi G, Lombardo M, Sessa F. COVID-19 and HHV8 first spotted together: an affair under electron microscopy. J Eur Acad Dermatol Venereol. 2021;35(5):e311-e312. doi:10.1111/jdv.17123
Yanes, Ryan R et al. “Detection of SARS-CoV-2 and HHV-8 from a large pericardial effusion in an HIV-positive patient with COVID-19 and clinically diagnosed Kaposi sarcoma: a case report.” Tropical medicine and health vol. 50,1 72. 24 Sep. 2022, doi:10.1186/s41182-022-00464-x
J, Dai L, Barrett L, et al. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. Commun Biol. 2021;4(1):682. Published 2021 Jun 3. doi:10.1038/s42003-021-02220-z
Cohen-Barak, Eran et al. “Kaposi's sarcoma in a patient with pemphigus vulgaris.” International journal of dermatology vol. 55,1 (2016): 85-8. doi:10.1111/ijd.12420
Wang, Tao et al. “Identification of human herpesvirus-8 in Kaposi's sarcoma with bullous pemphigoid.” Chinese medical journal vol. 127,4 (2014): 786-8.
Choi KH, Byun JH, Lee JY, Cho BK, Park HJ. Kaposi sarcoma after corticosteroid therapy for idiopathic thrombocytopenic purpura. Ann Dermatol. 2009;21(3):297-299. doi:10.5021/ad.2009.21.3.297
Simeoni, Sara et al. “Dermatomyositis complicated with Kaposi sarcoma: a case report.” Clinical rheumatology vol. 26,3 (2007): 440-2. doi:10.1007/s10067-005-0148-3
Zerbi S, Saruggia M, Brambilla L, Lodeville D, Buccianti G. Kaposi's sarcoma in a patient with focal glomerulosclerosis. J Nephrol. 2001;14(4):299-303.
L. Zhang, F. Zhu, L. Xie, C. Wang, J. Wang, R. Chen, P. Jia, H.Q. Guan, L. Peng, Y. Chen, P. Peng, P. Zhang, Q. Chu, Q. Shen, Y. Wang, S.Y. Xu, J.P. Zhao, M. Zhou, Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China, Annals of Oncology, vol. 31, Iss. 7, 2020, p. 894-901, ISSN 0923-7534, https://doi.org/10.1016/j.annonc.2020.03.296
